Supplementary Material

Supplementary Table S1. Pathological subtypes

Histology, *n* (%)	Lenvatinib (*n* = 103)	Placebo (*n* = 48)	Total (*N* = 151)
Papillary	83 (80.6)	40 (83.3)	123 (81.5)
Follicular variant	13 (12.6)	5 (10.4)	18 (11.9)
Other variants			
Columnar cell	2 (1.9)	0	2 (1.3)
Hürthle cell	1 (1.0)	2 (4.2)	3 (2.0)
Poorly differentiated	2 (1.9)	2 (4.2)	4 (2.6)
Other	0	2 (4.2)	2 (1.3)
Unknown	65 (63.1)	29 (60.4)	94 (62.3)
Follicular	20 (19.4)	8 (16.7)	28 (18.5)
Hürthle cell	1 (1.0)	0	1 (0.7)
Clear cell	0	1 (2.1)	1 (0.7)
Other	1 (1.0)	0	1 (0.7)
Unknown	18 (17.5)	7 (14.6)	25 (16.6)

Supplementary Figure S1. Forest plot of PFS hazard ratios for lenvatinib versus placebo (by IIR using RECIST v1.1)



CI, confidence interval; HR, hazard ratio; IIR, independent imaging review; NE, not estimable; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1; VEGF(R), vascular endothelial growth factor (receptor).

Supplementary Figure S2. Kaplan–Meier plot of OS[a] (full analysis set)



Number of patients at risk:

Lenvatinib	103	101	92	66	55	38	26	15	7	2	0
Placebo[a]	48	45	42	30	25	21	16	10	7	2	0

[a]The placebo group includes patients who received lenvatinib during the optional open-label phase.

CI, confidence interval; HR, hazard ratio; NE, not estimable; OS, overall survival.

Supplementary Figure S3. Kaplan–Meier plot of time to treatment failure



Number of patients at risk:

Lenvatinib	103	93	80	52	41	29	20	9	4	1	0
Placebo	48	33	25	12	5	3	2	2	0	0	0

CI, confidence interval; HR, hazard ratio, NE, not estimable.